IN BRIEF: Tiziana Life Sciences annual loss widens
IN BRIEF: Tiziana Life Sciences annual loss widens
Read moreWed, 04th Dec 2019 15:38
IN BRIEF: Tiziana Life Sciences annual loss widens
Read moreTRADING UPDATES: SIG in good start to 2021; Accsys taps EUR37 million
Read moreTRADING UPDATES: Clipper Logistics, JD Sports ink letter of intent
Read moreIN BRIEF: Tiziana plans phase II trials for nasal Covid-19 treatment
Read moreEXECUTIVE CHANGES: Iconic Labs CEO; Tiziana Hires Executive Director
Read moreTiziana Surges As Nasal Therapy May Be Effective In New Virus Variants
Read moreIN BRIEF: Tiziana Files US Statement Over USD250 Million Of Securities
Read moreUK EXECUTIVE CHANGE SUMMARY: Ex-Savills CEO To Be Tritax Big Box Chair
Read moreUK EXECUTIVE CHANGE SUMMARY: Premier Oil And DP Poland Board Changes
Read more(Sharecast News) - Biotechnology company Tiziana Life Sciences announced the completion of its clinical study in Brazil on Monday, investigating nasally-administered Foralumab - its proprietary human monoclonal antibody - either alone or in combination with orally administered dexamethasone in Covid-19 patients.
Read moreLONDON MARKET MIDDAY: Vaccine Rollouts, M&A And Gold Surge Boost FTSE
Read moreTiziana Announces Foralumab Trial Completion For Covid-19 Treatment
Read moreUK WINNERS & LOSERS SUMMARY: Tui Rises As Tips "Normal" Summer Trading
Read moreUK TRADING UPDATE SUMMARY: Polar Capital Adds GBP1.2 Billion To Assets
Read moreUK DIRECTOR DEALINGS SUMMARY: IG Design CEO Sells GBP528,000 In Shares
Read more